GT BIOPHARMA, INC. Capital Leases, Future Minimum Payments Due in Four Years
GT BIOPHARMA, INC. (GTBP) had Capital Leases, Future Minimum Payments Due in Four Years of $2.08 million as of 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Notes › Leases
us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears · last filed 2021-12-29
- 2021-09-30: Capital Leases, Future Minimum Payments Due in Four Years $2.08M.
- 2021-06-30: Capital Leases, Future Minimum Payments Due in Four Years $2.02M.
- 2018-09-30: Capital Leases, Future Minimum Payments Due in Four Years $61.00K.
| Period end | Capital Leases, Future Minimum Payments Due in Four Years |
|---|---|
| 2021-09-30 | $2.08M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $2.02M 10-Q/A · filed 2021-12-29 |
| 2018-09-30 | $61.00K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |